I would take a different perspective on this, one that is focused on consumer empowerment.
The CDR is a central planning mechanism focused on cost concerns. It needs to evaluate the pharmaco-economic value of drug technology and other health technologies—if we expand it to those—only because a government is the central payer that funds 100% of the costs in many of our plans. Countries that have an expanded formulary and make more drugs available to patients, or who have private insurance—which in fact makes all drugs declared safe and effective by Health Canada available to patients—employ different mechanisms. They preserve consumer choice by having deductible ranges that simply exclude those kinds of expenditures that are affordable for people and for which they should be paying out of pocket, and reserve insurance for things that are catastrophic or unaffordable on an individual basis, things that we should pool collectively. Those types of insurance programs also have co-payments that shift some of the costs to the patient, not just to shift costs, but also to influence their decisions on whether they should use the drug. They assess the value of it. If 100% of the cost is paid by their neighbours, they'll try it. But if there's a cost at the point of consumption—